Fresenius Kabi introduces pediatric cancer generic
LAKE ZURICH, Ill. — Fresenius Kabi announced on Tuesday the immediate availability in the United States of its first-to-market generic of Genzyme’s Clolar (clofarabine injection). Fresenius Kabi’s clofarabine injection is available as a single dose vial containing 20 mg per 20 mL clofarabine.
“Fresenius Kabi is pleased to introduce a generic version of this important pediatric cancer medicine,” said John Ducker, president and CEO of Fresenius Kabi USA. “Continuing to develop critical and accessible medicines for all patients is fundamental to the Fresenius Kabi mission of ‘caring for life.’”
Clofarabine injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate.
Lake Zurich-based Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.
Teva launches type 2 diabetes generic
JERUSALEM — Teva Pharmaceutical Industries launched generic Glumetza (metformin hydrochloride extended-release tablets), 500 mg and 1000 mg, in the United States.
Metformin hydrochloride extended-release tablets are used with diet and exercise to help control high blood sugar in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are not for people with type 1 diabetes or for people with diabetic ketoacidosis.
More than 28 million people in the U.S. are living with type 2 diabetes; a serious disease that can be managed through physical activity, diet and appropriate use of medications to lower blood sugar levels.
Glumetza is manufactured by Valeant Pharmaceuitcals. It had annual sales of approximately $1.03 billion in the U.S., according to IMS data as of March 2017.
QS/1 president Tammy Devine to retire
SPARTANBURG, S.C. — Pharmacy software solutions company QS/1 president Tammy Devine will be retiring later this year, the company announced Tuesday. There is currently a national search underway to find a successor for Devine, who joined the company as president in 2011.
“Tammy will be missed tremendously,” J M Smith chairman and CEO Alan Turfe said. “Her leadership at QS/1 has been phenomenal, and I am very grateful to her. I am very impressed with her strategic vision and the foundation she leaves behind — a committed and talented set of employees ready to embrace opportunities in the market.”
Devine was hired by the late Jim Smith in 1982 as a programmer, and she went on to hold various managerial positions, among them software development, marketing and operations. While she has been with QS/1, the company has grown to have a footprint in all 50 states, the District of Columbia and Puerto Rico.
“The time is right for me to step down,” Devine said. “Our latest product, SharpRx, has been successfully launched, we reorganized our processes to improve both quality and customer satisfaction and our employee engagement scores are at an all-time high. Leaving a company I love will naturally be hard, but everyone who knows me will tell you that I am looking forward to having more time to spend with my grandchildren.”
Devine has been a two-time president of the American Society for the Automation of Pharmacy and has held leadership with the Spartanburg Area Chamber of Commerce, and is currently on the board of the J M Smith Foundation, among other efforts in her community.